Literature DB >> 30061335

Guillain-Barré syndrome mimicking botulism in early disease course.

Robert Durcan1,2, Olwen Murphy1,2,3, Valerie Reid1, Tim Lynch1,2.   

Abstract

A 42-year-old man, returning to Europe after a 2-month stay in China, reported cough and runny nose. Five days later, he developed neck discomfort and rapidly evolving weakness, spreading from his arms to the facial, bulbar and neck muscles, and then the legs. He developed dysphagia and breathlessness, and was intubated in the emergency department. Cerebrospinal fluid showed mildly elevated protein. On day 2 he had fixed dilated pupils, with absent oculocephalic reflexes, and a flaccid upper limb paralysis. MR scans of the brain and spinal cord were normal. The early features of descending weakness, bulbar involvement and fixed dilated pupils made it difficult to distinguish between Guillain-Barré syndrome and botulism, and early investigations were inconclusive. We initially gave both botulinum antitoxin and intravenous immunoglobulin, but initially delayed plasma exchange as this would have removed the botulinum antitoxin. Diagnostic testing for botulism has low sensitivity, so we urge pre-emptive treatment if it is clinically suspected. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  botulinum toxin; guillain-barre syndrome; neuropathy

Mesh:

Substances:

Year:  2018        PMID: 30061335     DOI: 10.1136/practneurol-2018-001891

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  2 in total

1.  Botulism Mimicking Miller Fisher Syndrome.

Authors:  Luigi Sicurella; Anna Lisa Alfonzo; Simona Alessi; Lidia Urso; Matteo La Rosa
Journal:  Neurol Clin Pract       Date:  2021-06

2.  Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product.

Authors:  Deborah M Anderson; Veena R Kumar; Diana L Arper; Eliza Kruger; S Pinar Bilir; Jason S Richardson
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.